Having trouble accessing articles? Reset your cache.

Hustle and bustle at AIM

There is a growing belief among companies that London's Alternative Investment Market has shed the credibility concerns that once plagued it and is now an acceptable stock market for the blue chip international institutions that biotechs need. Last week, three companies listed on AIM, including two non-U.K. names, while a British company said it would move from LSE's main list to AIM.

"AIM is attractive because virtually all of the blue chip institutions have a proportion of their funds invested in AIM companies, and we are seeing increasing interest in this market from Continental European investors," Juliet Thompson, a banker with Nomura Code Securities, told BioCentury. "A significant proportion of the companies

Read the full 1121 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers